Transcenta Holding Limited

SEHK:6628 Voorraadrapport

Marktkapitalisatie: HK$409.1m

Transcenta Holding Beheer

Beheer criteriumcontroles 3/4

We currently do not have sufficient information about the CEO.

Belangrijke informatie

Xueming Qian

Algemeen directeur

CN¥5.6m

Totale compensatie

Percentage CEO-salaris20.3%
Dienstverband CEO12.1yrs
Eigendom CEO12.7%
Management gemiddelde ambtstermijn2.8yrs
Gemiddelde ambtstermijn bestuur3.2yrs

Recente managementupdates

Recent updates

Calculating The Intrinsic Value Of Transcenta Holding Limited (HKG:6628)

Dec 15
Calculating The Intrinsic Value Of Transcenta Holding Limited (HKG:6628)

Analyse CEO-vergoeding

Hoe is Xueming Qian's beloning veranderd ten opzichte van Transcenta Holding's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-CN¥359m

Mar 31 2024n/an/a

-CN¥411m

Dec 31 2023CN¥6mCN¥1m

-CN¥463m

Sep 30 2023n/an/a

-CN¥451m

Jun 30 2023n/an/a

-CN¥440m

Mar 31 2023n/an/a

-CN¥424m

Dec 31 2022CN¥6mCN¥1m

-CN¥407m

Sep 30 2022n/an/a

-CN¥666m

Jun 30 2022n/an/a

-CN¥925m

Mar 31 2022n/an/a

-CN¥2b

Dec 31 2021CN¥5mCN¥1m

-CN¥2b

Sep 30 2021n/an/a

-CN¥1b

Jun 30 2021n/an/a

-CN¥1b

Mar 31 2021n/an/a

-CN¥364m

Dec 31 2020CN¥51mCN¥1m

-CN¥317m

Dec 31 2019CN¥14mCN¥823k

-CN¥395m

Compensatie versus markt: Xueming's total compensation ($USD781.03K) is above average for companies of similar size in the Hong Kong market ($USD234.60K).

Compensatie versus inkomsten: Xueming's compensation has been consistent with company performance over the past year.

CEO

Xueming Qian (55 yo)

12.1yrs

Tenure

CN¥5,562,000

Compensatie

Dr. Xueming Qian, Ph.D. has been Chief Executive Officer and Executive Director at Transcenta Holding Limited and serves as its Chairman since June 07, 2024. He was the Founder, Chairman and Chief Executiv...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Xueming Qian
CEO & Executive Chairmanno dataCN¥5.56m12.71%
HK$ 52.0m
Xiaolu Weng
Executive VP & CFO2.9yrsCN¥8.32mgeen gegevens
Christopher Hwang
Executive VP of Process Development & CTO5.8yrsgeen gegevensgeen gegevens
Wei Wang
VP of Investor Relations & Capital Markets Department and Secretary to the Board2.7yrsgeen gegevensgeen gegevens
Yi Gu
Senior VP & Head of Research5.8yrsgeen gegevensgeen gegevens
Charlie Qi
Senior Vice President of Global Clinical Development1.8yrsgeen gegevensgeen gegevens
Xichen Zhang
Senior Vice President of Manufacturing & Quality2.8yrsgeen gegevensgeen gegevens
Wen-I Chang
Senior Vice President of Oncology Franchise Strategy2.6yrsgeen gegevensgeen gegevens
Caroline Germa
Executive VP of Global Medicine Development & Chief Medical Officer2.3yrsgeen gegevensgeen gegevens
Kwan Wai Leung
Company Secretary3.4yrsgeen gegevensgeen gegevens

2.8yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: 6628's management team is considered experienced (2.8 years average tenure).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Xueming Qian
CEO & Executive Chairman12.1yrsCN¥5.56m12.71%
HK$ 52.0m
Briggs W. Morrison
Chairman of Scientific Advisory Boardno datageen gegevensgeen gegevens
Pasi Antero Janne
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Kumar Srinivasan
Independent Non-Executive Director1.9yrsCN¥226.00kgeen gegevens
Ling Su
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Wei Chen
Independent Non-Executive Director1.3yrsCN¥72.00kgeen gegevens
Susan M. Jerian
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Li Xu
Member of Scientific Advisory Board3.8yrsgeen gegevens0.18%
HK$ 727.1k
Jiasong Tang
Independent Non-Executive Director3.2yrsCN¥219.00kgeen gegevens
Zhihua Zhang
Independent Non-Executive Director3.2yrsCN¥219.00kgeen gegevens

3.2yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren bestuur: 6628's board of directors are considered experienced (3.2 years average tenure).